---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-129367"
form_type: "8-K"
ticker: "BNBX"
cik: "0000744452"
company_name: "BNB PLUS CORP."
filed_at: "2024-12-17T23:59:59+00:00"
generated_at: "2026-05-29T02:38:46.212888+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Applied DNA posts FY2024 revenue of $3.4M, net loss $7.1M; announces restructuring and leadership changes

## Summary
- Q4 revenue $813K (up vs $780K YoY); FY revenue $3.4M vs $13.4M; net loss Q4 $3.3M ($0.32/sh), FY $7.1M ($1.82/sh).
- Pursuing divestiture of CertainT platform; targeting 15% opex reduction vs FY2024, expected by Q2 FY2025.
- Judith Murrah promoted to President (salary increased to $400K); Clay Shorrock named President of LineaRx subsidiary.
- GMP manufacturing facility buildout to complete by Jan 9, 2025; annual revenue capacity $4M-$16M depending on product mix.
- Raised $5.8M net in registered direct offering on Oct 31, 2024; cash ~$10.1M as of Nov 3, 2024.

## SEC filing metadata
- accession: 0001104659-24-129367
- form_type: 8-K
- ticker: BNBX
- cik: 0000744452
- company_name: BNB PLUS CORP.
- filed_at: 2024-12-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744452/000110465924129367/0001104659-24-129367-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744452/000110465924129367/tm2431261d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-129367
- JSON: https://secwatch.observer/filing/0001104659-24-129367.json
- Plain text: https://secwatch.observer/filing/0001104659-24-129367.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.